ReviewTherapeutic advances in gastroenterology2016
Hepatocellular adenoma: when and how to treat? Update of current evidence.
Review in Therapeutic advances in gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Gravitational 3D Magnetic Resonance Elastography for Differentiating Focal Nodular Hyperplasia and Hepatic Adenoma.Diagnostics (Basel, Switzerland) · 2026Article
- Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course.The British journal of radiology · 2024Review
- Hepatocellular Adenoma With Hepatocyte Nuclear Factor-1 Alpha (HNF-1α) Mutation: A Case Report.Cureus · 2024Article
- Spatial characterisation of β-catenin-mutated hepatocellular adenoma subtypes by proteomic profiling of the tumour rim.JHEP reports : innovation in hepatology · 2024Article
- A Scoping Review of the Classification, Diagnosis, and Management of Hepatic Adenomas.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Article
- Liver transplantation for benign liver tumors.World journal of hepatology · 2021Review
- Enlarged cystic artery.BMJ case reports · 2021Article
- From an Incidental Finding to an Emergent Treatment: A Case Report of a Hepatic Adenomatosis and Large Ruptured Hepatic Adenoma.Case reports in gastrointestinal medicine · 2021Article
- Benign Hepatic Tumors: From Incidental Imaging Finding to Clinical Management.Korean journal of family medicine · 2021Article
- Liver: glucose metabolism and 18F-fluorodeoxyglucose PET findings in normal parenchyma and diseases.American journal of nuclear medicine and molecular imaging · 2021Review
- Interventional radiological management of hepatobiliary disorders in pregnancy.Clinical and experimental hepatology · 2020Review
- ASS1 Overexpression: A Hallmark of Sonic Hedgehog Hepatocellular Adenomas; Recommendations for Clinical Practice.Hepatology communications · 2020Article
- Inflammatory Hepatocellular Adenoma with Elevated Serum Protein Induced by Vitamin K Absence/Antagonist-II in Adult Males.Internal medicine (Tokyo, Japan) · 2019Article
- Malignant transformation of hepatocellular adenoma in a young female patient after ovulation induction fertility treatment: A case report.World journal of gastrointestinal surgery · 2019Article
- Two-stage liver transplant for ruptured hepatic adenoma: A case report.World journal of hepatology · 2019Article
- Inflammatory hepatocellular adenoma in a patient with Turner's syndrome: A case report.International journal of surgery case reports · 2019Article
- Massive hepatic adenoma response to bland embolization: A case study.Radiology case reports · 2019Article
- Indications for liver surgery in benign tumours.European surgery : ACA : Acta chirurgica Austriaca · 2018Article
- 18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.PloS one · 2017Article
- A Rare Presentation of Multiple Hepatic Masses Due to Hepatic Adenoma: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular adenoma (HCA) is a rare, benign liver tumor. Discovery of this tumor is usually as an incidental finding, correlated with the use of oral contraceptives, or pregnancy. Treatment options have focused on conservative management for the straightforward, smaller lesions (<5 cm), with resection preferred for larger lesions (>5 cm) that pose a greater risk of hemorrhage or malignant progression. In recent years, a new molecular subclassification of HCA has been proposed, associated with characteristic morphological features and loss or increased expression of immunohistochemical markers. This subclassification could possibly provide considerable benefits in terms of patient stratification, and the selection of treatment options. In this review we discuss the decision-making processes and associated risk analyses that should be made based on lesion size, and subtype. The usefulness of this subclassification system in terms of the procedures instigated as part of the diagnostic work-up of a suspected HCA will be outlined, and suitable treatment schemes proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.